Novo Nordisk launches Changing Diabetes Barometer

Novo NordiskAt a media roundtable in Brussels, Novo Nordisk presented the Changing Diabetes Barometer, which will measure and share the worldwide progress in the fight against diabetes on an annual basis. The Barometer is a tool that will provide healthcare professionals, patient organisations, politicians, institutions and media with valuable information on how to improve the quality of diabetes care, bring down diabetes-related complications, extend patients' life expectancy and reduce costs.

"We have been driving the fight against diabetes in the dark for far too long. We need to put the lights on. We need to keep score of our shared efforts against diabetes to drive sustainable change. This is what the Changing Diabetes Barometer is about. It provides information on how we can better improve the lives of people with diabetes and how to better prioritise diabetes care," says Lise Kingo, executive vice president at Novo Nordisk.

To support the Changing Diabetes Barometer, Novo Nordisk will, on an annual basis, publish a report with key findings from the Barometer.

The first report covers 21 countries and highlights that significant savings, as much as 20% reduction of lifelong healthcare costs, can be made if people with diabetes are diagnosed earlier and before any complications arise. Furthermore, disease complications can be reduced by improving control. A person with complications is three to six times as expensive as a person without complications measured in healthcare costs. Disease complications can be serious, including kidney failure, limb amputations, blindness and cardiovascular disease.

The report highlights that doing nothing is costly, and that treating earlier and better reduces overall costs. If nothing is done, healthcare costs, social costs and the cost of lost productivity will increase dramatically as the number of people with diabetes rapidly rises.

It is not the number of people with diabetes in itself that is driving cost. It is the disease complications following late detection and poor control that put a heavy toll on healthcare systems.

"Despite estimates showing that the number of people with diabetes will rise to 380 million worldwide by 2025, the Changing Diabetes Barometer report shows that only a handful of countries have the necessary systems in place to measure diabetes and its effects on the population," says Professor Jean-Claude Mbanya, vice dean and professor of medicine and endocrinology at the University of Yaoundé, Cameroon. "If we act now by taking lessons from the Barometer, we can improve knowledge, treatment and awareness of the disease."

The report also highlights that more data is needed. Only seven out of the 21 countries examined in the first edition of the Barometer have data on important treatment indicators such as blood pressure, blood sugar and lipid levels. Furthermore, the report identifies that only three out of the 21 countries have systems in place to enable registration of data and consistent follow-up support for physicians.

Novo Nordisk hopes that the Barometer will become a framework to discuss and measure prevention, progress and treatment data.

About Novo Nordisk
Novo Nordisk is a healthcare company and a world leader in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 25,800 employees in 79 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit www.novonordisk.com.

Most Popular Now

NextPoint Therapeutics announces $80 million Serie…

NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-l...

AstraZeneca to acquire CinCor Pharma to strengthen…

AstraZeneca has entered into a definitive agreement to acquire CinCor Pharma, Inc. (CinCor), a US-based clinical-stage biopharmaceutical company, focused on developing no...

Bayer to accelerate drug discovery with Google Clo…

Bayer AG and Google Cloud announced a collaboration to drive early drug discovery that will apply Google Cloud's Tensor Processing Units (TPUs), which are custom-develope...

Incurable liver disease may prove curable

Research led by Associate Professor Duc Dong, Ph.D., has shown for the first time that the effects of Alagille syndrome, an incurable genetic disorder that affects the li...

Scientists develop a cancer vaccine to simultaneou…

Scientists are harnessing a new way to turn cancer cells into potent, anti-cancer agents. In the latest work from the lab of Khalid Shah, MS, PhD, at Brigham and Women’s ...

Acquisition of Neogene Therapeutics completed

AstraZeneca has completed the acquisition of Neogene Therapeutics Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and ...

Study identifies potential new approach for treati…

Targeting iron metabolism in immune system cells may offer a new approach for treating systemic lupus erythematosus (SLE) - the most common form of the chronic autoimmune...

Nanotechnology may improve gene therapy for blindn…

Using nanotechnology that enabled mRNA-based COVID-19 vaccines, a new approach to gene therapy may improve how physicians treat inherited forms of blindness. A collabo...

Modified CRISPR-based enzymes improve the prospect…

Many genetic diseases are caused by diverse mutations spread across an entire gene, and designing genome editing approaches for each patient’s mutation would be impractic...

Pfizer expands 'An Accord for a Healthier World' p…

Pfizer Inc. (NYSE: PFE) announced that it has significantly expanded its commitment to An Accord for a Healthier World to offer the full portfolio of medicines and vaccin...

500,000 missed out on blood pressure lowering drug…

Nearly half a million people missed out on starting medication to lower their blood pressure during the COVID-19 pandemic, according to research supported by the British ...

Roche announces the European Commission approval o…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the European Commission (EC) has approved Xofluza® (baloxavir marboxil) in children aged one year and above for the trea...